Japan – Pfizer and Eisai Commence Co-promotion of “NURTEC(R)” for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi,”Pfizer”) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) revealed today that the business will begin the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor villain Nurtec ® OD Tablet 75mg (generic name: rimegepant sulfate hydrate …